{"title":"规范:新原料药和新制剂的试验程序和验收标准:化学物质","authors":"Sarfaraz K Niazi","doi":"10.3109/9781420081275-15","DOIUrl":null,"url":null,"abstract":"ensure product quality and process / batch consistency, supplemented by current Good Manufacturing Practices (cGMP) and thorough product understanding. The guidance was developed for the approval of commercial products and was not intended for clinical development, although the concepts are still applicable. During development, knowledge of critical quality attributes (CQAs) may be limited, as significant changes in both synthesis / process (API) and formulation / process (drug product) would be anticipated. ICH M3 provides some useful insight for qualifying impurities during the development phase:","PeriodicalId":238873,"journal":{"name":"Handbook of Pharmaceutical Manufacturing Formulations, Second Edition","volume":"27 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2016-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"48","resultStr":"{\"title\":\"Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances\",\"authors\":\"Sarfaraz K Niazi\",\"doi\":\"10.3109/9781420081275-15\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"ensure product quality and process / batch consistency, supplemented by current Good Manufacturing Practices (cGMP) and thorough product understanding. The guidance was developed for the approval of commercial products and was not intended for clinical development, although the concepts are still applicable. During development, knowledge of critical quality attributes (CQAs) may be limited, as significant changes in both synthesis / process (API) and formulation / process (drug product) would be anticipated. ICH M3 provides some useful insight for qualifying impurities during the development phase:\",\"PeriodicalId\":238873,\"journal\":{\"name\":\"Handbook of Pharmaceutical Manufacturing Formulations, Second Edition\",\"volume\":\"27 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2016-04-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"48\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Handbook of Pharmaceutical Manufacturing Formulations, Second Edition\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3109/9781420081275-15\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Handbook of Pharmaceutical Manufacturing Formulations, Second Edition","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3109/9781420081275-15","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances
ensure product quality and process / batch consistency, supplemented by current Good Manufacturing Practices (cGMP) and thorough product understanding. The guidance was developed for the approval of commercial products and was not intended for clinical development, although the concepts are still applicable. During development, knowledge of critical quality attributes (CQAs) may be limited, as significant changes in both synthesis / process (API) and formulation / process (drug product) would be anticipated. ICH M3 provides some useful insight for qualifying impurities during the development phase:
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
